INTRODUCTION
Enterobacteriaceae group is the main cause of bacterial infection [1] in the world and in this family Escherichia coli and Klebsiella spp. are the most prevalent causes of nosocomial infection. [1, 2] These pathogens are responsible for a broad spectrum of clinical infections in immune competent or immune compromised people and also, have a key role in epidemics of nosocomial infections in many hospitals. [3] Extended-spectrum β-lactamases (ESBLs) represents a major threat among multidrug-resistant bacteria isolates. They have risen to prominence among Enterobacteriaceae isolates in nearly all countries, now not only in the nosocomial but also in the community se ing. [4, 5] These ESBL producing pathogens are now recognized globally as major causes of nosocomial and community-acquired infections.
inhibition by all commercially viable β-lactamase inhibitors. Four classes are available in this group: Molecular classes A, C, and D include the β-lactamases with serine at their active site, whereas molecular class B β-lactamases are all metalloenzymes with zinc in active-site. Klebsiella pneumoniae carbapenemase (KPC) enzymes are belonging to class A carbapenemases that reside on transferable plasmids and can hydrolyze all penicillins, cephalosporins, and carbapenems. [8] The emergence of acquired metallo-β-lactamases (MBLs) has clinical and epidemiological implications and is a ma er of particular concern worldwide. [9] The options for treating infections caused by KPCs and MBLs are limited and their epidemiology remains largely unknown in Iran. The aim of this study was to determine the prevalence of ESBL, KPCs, and MBLs producing E. coli and Klebsiella to reduce the antibiotic therapy failure in Al-Zahra Hospital, Isfahan.
MATERIALS AND METHODS
This cross-sectional study was performed in Al-Zahra Hospital (Isfahan University of Medical Sciences) from March to December 2012. The study was approved by the Ethical Commi ee of Isfahan University of Medical Sciences, Isfahan, Iran (project number: 391327). Midstream urine samples from hospitalized or referred patients with acute urinary tract infection (UTI) were obtained and evaluated for the presence of leucocytes and/or bacteriuria. Samples were cultured on blood agar and Eosin Methylene Blue agar mediums (purchased from Himedia Company, India) and incubated at 35°C for 18-24 h. All patient samples with urine cultures yielding growth of ≥10 5 CFU/ml E. coli and Klebsiella spp. were included in the study. The pure isolates identifi ed according to Gram stains and biochemical tests.
Antibiotic susceptibility test
Antibiotic sensitivity pattern of isolates to common antibiotics used in the hospital was determined by the Kirby Bauer's disc diff usion method on Mueller-Hinton agar. Choice of antibiotic disks was determined by Clinical Laboratory Standard Institute (CLSI) guidelines. [10] All hospitalized isolates were tested against ampicillin (AMP 10 μg), piperacillin-tazobactam 100 μg, CAZ 30 μg, CTX 30 μg, IPM 10 μg, MEM 10 μg, ertapenem (ERT 10 μg), amikacin (AMK 30 μg), ciprofloxacin (CIP 5 μg), and nitrofurantoin (NIT 30 μg). All non-hospitalized isolates were tested against AMP 10 μg, CAZ 30 μg, CTX 30 μg, IPM 10 μg, MEM 10 μg, ERT 10 μg, gentamicin 10 μg, CIP 5 μg, trimethoprim/sulfamethoxazole (SXT 1.2 μg), and NIT 30 μg. All antimicrobial disks used for susceptibility testing were obtained from BD BBL Sensi-Disc (Becton Dickinson, Sparks, MD, USA). E. coli ATCC 25922 and K. pneumoniae ATCC 700603 were used for quality control as recommended by CLSI. The plates were incubated at 35°C for 18 h. The degree of susceptibility of the test isolate to each antibiotic was interpreted as sensitive (S), intermediate resistant (I) or resistant (R) by measuring the zone diameter of inhibition. [10] Phenotypic detection of ESBLs production The ESBL-producing were determined by the phenotypic method using screening Kirby-Bauer disk diff usion method in CAZ or CTX resistance isolates. A confi rmatory test of ESBL-production was performed with the double-disk (combined-disk) method. [10, 11] The zones of inhibition of each isolate were tested on Mueller-Hinton agar plates with the disks containing 30 g of CAZ and CTX alone and in combination with 10 g of clavulanic acid, respectively (all above disk purchased from Mast Company). An organism was classifi ed as having an ESBL producing phenotype if the zone of inhibition produced by at least one combination disk was more than 5 mm larger than that produced by the corresponding antimicrobial disk without clavulanic acid.
Phenotypic detection of KPC
All isolates with resistance to IPM and MEM were tested for the production of KPC carbapenemase production by the modified Hodge test (MHT) method. [10, 12] The MHT was carried out according to CLSI guidelines using ERT 10 μg disk on Mueller-Hinton agar plates. The presence of a "cloverleaf shaped" inhibition zone a er overnight incubation was indicated as a positive test result. For confirmatory of carbapenem resistance minimum inhibitory concentration (MIC) determined using E-test method. E. coli ATCC 25922 was used as a carbapenem susceptible strain.
Phenotypic detection of MBL
In addition, all isolates with resistance to IPM and MEM were tested for the MBLs production by IPM-ethylenediaminetetraacetic acid (EDTA) combined disc method that in positive strains zone of inhibition of IPM with EDTA (IMP + EDTA) is greater than IMP alone by 5 mm. [9] For confi rmatory of carbapenem resistance MIC determined using E-test method. The Pseudomonas aeruginosa ATCC 27853 strain was used as negative control.
Statistical analyses
Diff erences between proportions were analyzed using the Chi-square test. The null hypothesis was rejected for values of P < 0.001. Statistical analyses were performed with SPSS version 17 so ware (SPSS Inc., USA) and Microso Offi ce Excel.
RESULT
During March 2012 to December 2012 a total of 1564 consecutive urine clinical isolates including 1080 of E. coli and 484 of Klebsiella spp. were collected. Table 1 shows the sex and hospitalized and non-hospitalized distribution in patients and the overall prevalence of E. coli and Klebsiella in the urine samples. Females had higher overall prevalence than the males as shown in Table 1 (P < 0.001).
Resistant to CAZ and CTX among E. coli and Klebsiella isolates is shown in Table 2 . Confi rmatory test of ESBLproduction in these resistance isolates showed among 720 E. coli hospitalized isolates, 300 (41.7%) and among 360 nonhospitalized isolates, 90 (25%) were ESBLs producers. These data for Klebsiella were 198 (51.5%) among 384 hospitalized isolates and 40 (40%) among 100 non-hospitalized isolates [ Table 3 ] (P < 0.001).
In addition, resistance to IPM, MEM, and ERT is shown in Table 2 that these isolates were selected for detection of MBL and KPC carbapenemases producing. As shown in Table 3 , prevalence of MBL producing in hospitalized E. coli and Klebsiella spp. were 0.3% (2/720) and 2.6% (10/384), respectively. No MBL producing isolate detected in non-hospitalized E. coli and Klebsiella. Carbapenem resistance determined using MIC by E-test method.
Prevalence of KPC carbapenemases producing that was confi rmed by the MHT in hospitalized E. coli and Klebsiella spp. were 1.4% (10/720) and 48.4% (186/384) respectively [ Table 3 ]. No KPC carbapenemases producing isolate was seen in non-hospitalized E. coli, but one non-hospitalized Klebsiella was KPC producer (P < 0.001). Carbapenem resistance determined using MIC by E-test method. Table 4 shows the susceptibility and resistance percentages of the non-hospitalized and hospitalized E. coli and Klebsiella isolates. In non-hospitalized Klebsiella and E. coli isolates, more resistance were seen to AMP and SXT, (P < 0.001). In hospitalized E. coli and Klebsiella isolates AMK and NIT were eff ective antibiotics (P < 0.001).
DISCUSSION
ESBL is associated with Enterobacteriaceae species, mostly K. pneumoniae, E. coli, and Enterobacter spp. [13] Since the 1980s, ESBLs producing Gram-negative bacteria have been isolated in many countries. [14] Many outbreaks caused by such bacteria, especially E. coli and K. pneumoniae have been reported. [15] [16] [17] [18] [19] [20] (74) 12 (3) 88 (23) 41 (41) (2) 1 (1) 97 (97) E. coli = Escherichia coli; R = Resistant; I = Intermediate resistant; S = Susceptible; N = Number; ESBL = Extended spectrum β-lactamase; MBL = Metallo-β-lactamase; KPC = Klebsiella pneumoniae carbapenemase [21] One of the earliest documented reports of the occurrence of ESBL phenotypes comes from Korea, with 7.5% of E. coli and 22.8% of K. pneumonia isolates at Yonsei Medical Center being described as ESBL-positive in 1994. [22] Studies by Kawakami et al. [23] from a hospital in Tokyo reported rates of 0.4% and 0.6% in E. coli and K. pneumoniae, respectively, in 1990, rising to 1.7% and 7.2% in 1995. A survey of seven laboratories in the Kinki region, over 2-month periods in 1998 and 2000, revealed 10% of E. coli isolates and 4.0% of K. pneumoniae isolates to have an ESBLs phenotype. [24] In another survey in Pakistan by Zaman et al., of 200 nosocomial isolates of Enterobacteriaceae, reported a rate of 35%. A comprehensive study and community isolates of E. coli, Klebsiella spp., and Enterobacter spp. revealed ESBL phenotype rates of 41%, 36%, and 50%, respectively. [25] A total of 67.2% of isolates in a study conducted in Tehran, Iran were confi rmed as ESBL positive, [26] however, in another study this rate was reported 89.3%. [27] Mirsalehian et al. found that 60.6% isolates of E. coli were producers of ESBLs. [28] Like other investigation in Iran hospitals, our results showed high ESBLs prevalence in both hospitalized and non-hospitalized E. coli and Klebsiella isolates.
Carbapenemase-producing bacteria such as KPC and MBLs producing bacteria represents a major threat to human health because of fails in most antibiotic therapy. [29] In recent years, the detection of these enzyme among Gram-negative bacilli has been reported from diff erent countries, including Iran. [9] However, these reports in Iran are very incomplete and need to be more investigated. In a study by Deshpande et al. [30] in United States prevalence of carbapenemases among 8885 Enterobacteriaceae isolates was only 51 isolates. In addition, study of Bratu et al. [31] showed 24% KPC producing among K. pneumoniae isolates. High KPC producing prevalence (48.4%) in our study represents a major concern in Isfahan province. Also result of our study showed that KPC is main carbapenem resistance mechanism in Klebsiella and E. coli isolates and MBLs producing isolates are rare in investigated hospital.
Comparing of antibiotics resistant percentage in nonhospitalized and hospitalized isolates showed that both non-hospitalized and hospitalized isolates were more resistant to AMP. AMK and NIT were the effective antibiotics against hospitalized both Klebsiella and E. coli isolates.
CONCLUSION
Result of our study showed high prevalence of ESBLs and KPC but low prevalence of MBLs in cultured bacteria from urine samples of patients with acute UTI. In addition, KPC was the main carbapenem resistance mechanism in Klebsiella and E. coli isolates.
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